Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems

[1]  S. Freedland,et al.  Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. , 2012, Urology.

[2]  H. Henk,et al.  Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases , 2012, Journal of medical economics.

[3]  H. Henk,et al.  Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers , 2012, Journal of medical economics.

[4]  Swu-Jane Lin,et al.  Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. , 2011, Clinical breast cancer.

[5]  J. V. Von Roenn,et al.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Wu,et al.  The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population , 2011, Prostate Cancer and Prostatic Diseases.

[7]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[8]  J. Mohler.  The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  Swu-Jane Lin,et al.  Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases , 2008, Cancer.

[10]  J. Goodwin,et al.  Use of intravenous bisphosphonates in older women with breast cancer. , 2008, The oncologist.

[11]  J. Mortimer,et al.  Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. , 2007, Clinical breast cancer.

[12]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Hillner,et al.  American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer , 2000 .

[14]  R. Theriault,et al.  Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer , 2013 .

[15]  C. Goodman.  Policy Analysis, Inc. , 1988 .